5PSQ-050 Neuropsychiatric adverse effects on dolutegravir: experience in a third-level hospital

BACKGROUND: Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is currently among the most commonly used antiretroviral agents. Recent reports have raised concerns about their safety, especially with regard to neuropsychiatric adverse effects (neuropsychiatric AEs)....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Lopez, TLopez Viñau, de Molina, MD López Malo, de Vicente, M Sáez-Torres, Donoso, J López-Santamaria, Torres, IReyes, Parada, J Hernández
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 5: Patient safety and quality assurance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535272/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.404
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados